Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Rosenbaum

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
American Journal of Physiology. Renal Physiology|December 7, 2020
Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in ratsAndrew J King, Jill Kohler, Cyra Fung, et al.
Drug Design, Development and Therapy|September 19, 2017
Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonateVanessa Zann, John McDermott, Jeffrey W Jacobs, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|July 11, 2024
Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney FailureKathleen M Hill Gallant, Stuart M Sprague, David P Rosenbaum, et al.
Neurogastroenterology and Motility|September 5, 2023
Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 studyAnthony J Lembo, Keith A Friedenberg, Ronald P Fogel, et al.
Journal of the American Society of Nephrology : JASN|February 5, 2017
Effect of Tenapanor on Serum Phosphate in Patients Receiving HemodialysisGeoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Kidney360|October 19, 2023
Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE StudyArnold L Silva, Glenn M Chertow, German T Hernandez, et al.
Kidney360|April 4, 2022
Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)Geoffrey A Block, Anthony J Bleyer, Arnold L Silva, et al.
Kidney360|May 7, 2026
Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)Geoffrey A Block, Anthony J Bleyer, Arnold L Silva, et al.
Clinical Pharmacology in Drug Development|September 23, 2016
Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate BindersSusanne Johansson, Maria Leonsson-Zachrisson, Mikael Knutsson, et al.
Journal of Clinical Pharmacology|April 13, 2018
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675Bertram Pitt, Vanessa Zann, Chris Roe, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
American Journal of Physiology. Renal Physiology|December 7, 2020
Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in ratsAndrew J King, Jill Kohler, Cyra Fung, et al.
Drug Design, Development and Therapy|September 19, 2017
Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonateVanessa Zann, John McDermott, Jeffrey W Jacobs, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|July 11, 2024
Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney FailureKathleen M Hill Gallant, Stuart M Sprague, David P Rosenbaum, et al.
Neurogastroenterology and Motility|September 5, 2023
Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 studyAnthony J Lembo, Keith A Friedenberg, Ronald P Fogel, et al.
Journal of the American Society of Nephrology : JASN|February 5, 2017
Effect of Tenapanor on Serum Phosphate in Patients Receiving HemodialysisGeoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Kidney360|October 19, 2023
Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE StudyArnold L Silva, Glenn M Chertow, German T Hernandez, et al.
Kidney360|April 4, 2022
Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)Geoffrey A Block, Anthony J Bleyer, Arnold L Silva, et al.
Kidney360|May 7, 2026
Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)Geoffrey A Block, Anthony J Bleyer, Arnold L Silva, et al.
Clinical Pharmacology in Drug Development|September 23, 2016
Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate BindersSusanne Johansson, Maria Leonsson-Zachrisson, Mikael Knutsson, et al.
Journal of Clinical Pharmacology|April 13, 2018
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675Bertram Pitt, Vanessa Zann, Chris Roe, et al.
Pageof 4